« Back
Home /
Osimertinib (dimesylate)

Osimertinib (dimesylate)

Item no.	HY-79077-100mg
Manufacturer	MedChem Express
CASRN	2070014-82-1
Amount	100 mg
Quantity options	100 mg 10mM/1mL 10 mg 200 mg 500 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.96
Formula	C30H41N7O8S2
Citations	Research Square Preprint. 2021 May.<br/>ACS Nano. 2022 Jul 21.<br/>Acta Pharmacol Sin. 2019 Dec;40(12):1587-1595. <br/>Acta Pharmacol Sin. 2021 Jan 7.<br/>Acta Pharmacol Sin. 2021 Jan;42(1):108-114.<br/>Adv Sci (Weinh). 2024 May 2:e2306348.<br/>Am J Cancer Res. 2023 Sep 15;13(9):4145-4162.<br/>Am J Transl Res. 2021 Jun 15;13(6):6055-6065.<br/>Anticancer Res. 2019 Sep;39(9):4817-4828.<br/>Biomed Pharmacother. 2024 Jan 9:171:116124.<br/>Bioorg Chem. 2023 Mar 27.<br/>bioRxiv. 2023 Oct 27.<br/>bioRxiv. 2024 Feb 12.<br/>Cancer Cell Int. 2021 Apr 15;21(1):216.<br/>Cancer Cell Int. 2021 Jul 3;21(1):337.<br/>Cancer Discov. 2019 Jul;9(7):926-943.<br/>Cancer Gene Ther. 2022 Sep 19.<br/>Cancer Res Treat. 2023 Jan 26.<br/>Cancer Res. 2023 Apr 16;CAN-22-3059.<br/>Cancer Res. 2023 Dec 14.<br/>Cancer Res. 2023 May 2;83(9):1490-1502.<br/>Cancers. 2019 Jul 5;11(7):947.<br/>Cancers. 2019 Oct 14;11(10):1550.<br/>Cell Chem Biol. 2018 Aug 16;25(8):996-1005.e4.<br/>Cell Death Differ. 2024 May 30.<br/>Cell Death Dis. 2019 Aug 13;10(8):615.<br/>Cell Death Dis. 2019 May 1;10(5):361. <br/>Cell Oncol. 2022 Sep 21.<br/>Cell Rep Med. 2023 Jan 10;100911.<br/>Cell Rep Med. 2024 Mar 19;5(3):101471.<br/>Commun Biol. 2021 Dec 13;4(1):1391.<br/>Drug Deliv Transl Res. 2021 Nov 23.<br/>Drug Metab Pharmacokinet. 2020 Oct;35(5):456-465.<br/>Environ Toxicol. 2019 Apr;34(4):476-485. <br/>Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.<br/>Eur J Pharmacol. 2021, 174297.<br/>Faculty of Medicine. University of Oslo. 2019 Feb.<br/>Fundam Clin Pharmacol. 2021 Feb 1.<br/>Genes Cancer. 2017 Mar;8(3-4):497-504.<br/>Int Immunopharmacol. 2023 Nov 23:126:111265.<br/>Int J Anal Chem. 2020 Dec 29.<br/>Int J Biol Macromol. 2024 May;268(Pt 1):131560.<br/>Int J Biol Sci. 2021; 17(7):1671-1681.<br/>Int J Mol Med. 2023 Nov;52(5):102.<br/>Int J Mol Sci. 2023 May 15, 24(10), 8794.<br/>Int J Oncol. 2020 Jan;56(1):243-257.<br/>J Biol Chem. 2023 May 11;104814.<br/>J Cell Physiol. 2021 Nov 21.<br/>J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100.<br/>J Exp Clin Cancer Res. 2019 Mar 15;38(1):129.<br/>J Exp Clin Cancer Res. 2019 Mar 15;38(1):129. <br/>J Exp Clin Cancer Res. 2019 May 23;38(1):219. <br/>J Med Chem. 2017 Apr 13;60(7):2944-2962. <br/>J Med Chem. 2023 Apr 11.<br/>J Nat Med. 2023 Apr 12.<br/>J Natl Cancer Inst. 2023 Jul 22;djad142.<br/>J Pharm Anal. 2021 Jun 19.<br/>Mol Cancer Res. 2019 Feb;17(2):499-507. <br/>Mol Cancer Res. 2019 Nov;17(11):2233-2243.<br/>Mol Cancer Ther. 2018 Mar;17(3):603-613.<br/>Mol Cancer Ther. 2019 May;18(5):920-928.<br/>Mol Cancer Ther. 2023 Sep 5;22(9):1013-1027.<br/>Mol Med Rep. 2021 Jan;23(1):48.<br/>Mol Oncol. 2023 Apr 4.<br/>Mol Pharmacol. April 5, 2022.<br/>Nat Cancer. 2022 Apr;3(4):402-417.<br/>Nat Cancer. 2023 Jun;4(6):829-843.<br/>Oncogene. 2022 May;41(22):3104-3117.<br/>Oncol Lett. 2023 Jul 20.<br/>Oncotarget. 2015 Oct 13;6(31):31313-22. <br/>Oncotarget. 2016 Oct 25;7(43):69760-69769.<br/>Oncotarget. 2017 Mar 14;8(11):18359-18372. <br/>Patent. US20190010159A1.<br/>Patent. US20200276189A1.<br/>Patent. US20210315911A1.<br/>Patent. US20230158019A1.<br/>Research Square Preprint. 2021 Jul.<br/>Research Square Preprint. 2021 Jun.<br/>Research Square Preprint. 2021 Mar.<br/>Research Square Preprint. 2021 May.<br/>Research Square Preprint. 2023 May 5.<br/>Research Square Preprint. 2024 Jan 3.<br/>Research Square Print. December 21st, 2022.<br/>Respir Physiol Neurobiol. 2020 Oct;281:103496.<br/>Respir Res. 2024 May 20;25(1):215.<br/>RSC Chem Biol. 2023 Aug 29.<br/>Theranostics. 2021 Jan 19;11(7):3392-3416.<br/>Theranostics. 2021 Mar 24;11(12):5650-5674.<br/>Universitat Politècnica de València. 2021 Sep.<br/>Cancer Cell. 2020 Jan 13;37(1):104-122.e12.<br/>Cancer Lett. 2023 May 19;216237.<br/>Commun Biol. 2024 Mar 1;7(1):250.<br/>Oncotarget. 2017 Dec 6;9(2):1641-1655.<br/>Research Square Preprint. 2023 Jun 30.<br/>Xenobiotica. 2018 Nov;48(11):1106-1112.<br/>[1]Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.<br/>[2]Finlay MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistancemutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67.
Smiles	CS(=O)(O)=O.C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O.CS(=O)(O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AZD-9291 (dimesylate); Mereletinib (dimesylate)
Available
Product Description	Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	691.82
Clinical Information	Launched
Manufacturers Research Area	Cancer
Solubility	DMSO : 2.63 mg/mL (ultrasonic)\|H2O : 100 mg/mL (ultrasonic)
Target	EGFR
Manufacturers Target	EGFR
Isoform	EGFR/ErbB1/HER1
Manufacturers Pathway	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-79077-100mg-safety-datasheet.pdf